The Endocrine Society has selected 13 leaders in the endocrinology field as winners of its prestigious 2019 Laureate Awards. Among the recipients is James W. Findling, MD, an expert in Cushing’s disease. Each recipient will be presented with the award at ENDO 2019,…
News
Medical therapy using cabergoline is an option for treating patients with persistent or recurrent Cushing’s disease after transsphenoidal surgery, new research from India shows. The study, “Effect of cabergoline monotherapy in Cushing’s disease: an individual participant data meta‑analysis,” was published in the Journal of Endocrinological Investigation. Cushing’s disease is most…
Minimally invasive diagnostic methods and transnasal surgery may lead to remission in nearly all children with Cushing’s disease, while avoiding more aggressive approaches such as radiation or removal of the adrenal glands, a study shows. The study, “A personal series of 100 children operated for Cushing’s…
OvaScience and Millendo Therapeutics will merge in an all-stock deal to push forward Millendo’s lead candidates livoletide (AZP-531) and nevanimibe (ATR-101) for the treatment of Prader-Willi syndrome and Cushing’s syndrome, respectively. An investor group that includes New Enterprise Associates, Frazier Healthcare Partners, Roche…
Recorlev (levoketoconazole) safely and successfully reduces the levels of cortisol in patients with endogenous Cushing’s syndrome, according to top-line results of a Phase 3 clinical trial. Cushing’s syndrome occurs due to abnormally high levels of cortisol, mainly caused by prolonged exposure to cortisol-like steroid medications and less commonly by…
A test using betamethasone — a corticosteroid that causes the pituitary gland to stop producing ACTH – can accurately predict short- and long-term remission in Cushing’s disease patients who have had pituitary surgery, a retrospective study reports. The research, “An early post-operative ACTH suppression test can safely predict short- and long-term…
Korlym (mifepristone) is effective for the treatment of ectopic Cushing’s syndrome patients, with survival rates comparable to patients who undergo bilateral adrenalectomy (removal of the adrenal glands), new research shows. The study, “Mifepristone in the treatment of the ectopic adrenocorticotropic hormone syndrome,” was published in the journal…
American and Dutch patients with Cushing’s syndrome have different ways of interpreting the same items on a disease-specific quality-of-life (QoL) questionnaire, research shows. The study, “Assessing Differences in How the CushingQoL Is Interpreted Across Countries: Comparing Patients From the U.S. and the Netherlands,” was published in…
Metformin, Oral Diabetes Treatment, Limits Growth of Tumors That Cause Cushing’s in Early Study
Metformin, an oral type 2 diabetes medicine, can promote cell death in tumors that cause Cushing’s disease and reduce the excessive production of the adrenocorticotroph hormone (ACTH) that underlies it, a study in mice cells reports. These findings suggest that metformin, a tablet, may offer a new way of treating…
Salivary cortisol levels can be used to diagnose Cushing’s syndrome with relatively high reliability, but each test center should establish its own measurement limits depending on the exact method used for the test, a study from Turkey shows. Researchers, however, caution that late-night salivary cortisol measurements in clinical practice…
Recent Posts
- Stuck at the intersection of anxiety and insomnia
- Cushing’s syndrome greatly raises risk of hospitalization for infections
- Tumor cells left behind in surgery can cause Cushing’s recurrence, per report
- Building strength, even with Cushing’s, so I can be there for my daughter
- Corcept gives FDA new relacorilant data in resubmitted application
- Toddler develops Cushing’s syndrome from topical steroid use
- Seeing is believing: How Cushing’s disease affects my vision
- Asedebart normalizes cortisol levels in most Cushing’s patients: Data
- My Cushing’s disease brain fog has a mind of its own
- Korlym improves results for diabetes patients taking GLP-1 drugs